Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptamer Group Regulatory News (APTA)

Share Price Information for Aptamer Group (APTA)

Share Price is delayed by 15 minutes
Get Live Data
0.525    0.00 (0.00%)
Bid:
0.50
Ask:
0.55
Spread: 0.05 (10.00%)
Market Cap: £18.14m
APTA Live PriceLast checked at - London Stock Exchange

Intraday Aptamer Group Share Chart

Holding(s) in Company

28 Jul 2025 12:25

RNS Number : 8329S
Aptamer Group PLC
28 July 2025
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Aptamer Group plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Mr Nicholas Slater

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

28 July 2025

6. Date on which issuer notified (DD/MM/YYYY):

28 July 2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

5.57

5.57

148,133,333

Position of previous notification (if

applicable)

6.48

6.48

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BNRRP542

148,133,333

-

5.57

-

SUBTOTAL 8. A

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

London, UK

Date of completion

28 July 2025

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLPPUCPMUPAGGR
Date   Source Headline
13th Apr 20261:08 pmRNSResult of General Meeting
31st Mar 20267:00 amRNSResult of Retail Offer and Posting of Notice of GM
26th Mar 20267:05 amRNSRetail Offer to raise up to £0.5 million
26th Mar 20267:00 amRNSResults of Placing
25th Mar 20267:10 amRNSInterim Results and Notice of Investor Webinar
25th Mar 20267:00 amRNSProposed Placing, Subscription and Retail Offer
18th Mar 20267:00 amRNSLaunch of targeted radiopharmaceutical programme
10th Mar 20263:26 pmRNSBlock Listing Interim Review
17th Feb 20267:00 amRNS-RTechnical Feasibility for Pathogen Detector
11th Feb 20267:00 amRNSOptimer® Technology in Launched Library Prep Kit
29th Jan 20267:00 amRNSContract wins and first cash licensing receipts
7th Jan 20264:04 pmRNSTrading update - Media comment and speculation
7th Jan 20267:00 amRNSHalf Year Trading Update
23rd Dec 20257:00 amRNSAptamer signs licensing agreement with Alphazyme
23rd Dec 20257:00 amRNSAptamer signs licensing agreement with Alphazyme
16th Dec 202510:34 amRNSLicensing agreement with Twist Bioscience
27th Nov 20251:01 pmRNSResults of 2025 Annual General Meeting
27th Nov 20257:00 amRNSAGM Statement
14th Nov 20257:00 amRNSStrong contract wins build commercial momentum
4th Nov 20257:00 amRNSNew contract with top five pharma company
3rd Nov 20257:00 amRNSPosting of Annual Report and Notice of AGM
14th Oct 20257:00 amRNSFull Year Results for the 12mths to 30 June 2025
13th Oct 20257:00 amRNSNew contract with top 10 pharma
10th Oct 20257:00 amRNSNotice of Results, Analyst & Investor Presentation
8th Oct 20257:00 amRNSMajor top 3 global pharma contract win
26th Sep 20257:00 amRNS-RInvestor Event and Presentation
11th Sep 20257:00 amRNS-RNew contract with Metir plc
9th Sep 20257:00 amRNSNotification of dealings by a director/PDMR
2nd Sep 20257:00 amRNSTherapeutic development agreement with Invizius
28th Aug 20257:00 amRNSBlock Listing Interim Review
27th Aug 20257:00 amRNSBiomarker Discovery Service Launch
22nd Aug 20257:00 amRNSUpdate on licensing and development progress
19th Aug 20257:00 amRNSExercise of warrants
18th Aug 20253:44 pmRNSHolding(s) in Company
18th Aug 20257:00 amRNSContract extension with global pharma partner
8th Aug 20257:00 amRNS-RInvestor Technical Webinar
7th Aug 20255:24 pmRNSHolding(s) in Company
5th Aug 20258:05 amRNSHolding(s) in Company
31st Jul 20251:29 pmRNS-RInvestor Webinar
31st Jul 20257:00 amRNSTrading Update
28th Jul 202512:25 pmRNSHolding(s) in Company
24th Jul 202511:48 amRNSResult of General Meeting
21st Jul 20257:00 amRNSAdditional work commissioned by Unilever
18th Jul 20257:00 amRNSIssue of Equity in lieu of Non-Exec Director Fees
9th Jul 20252:53 pmRNSHolding(s) in Company
8th Jul 20257:00 amRNSPosting of Circular and Notice of General Meeting
4th Jul 20257:00 amRNSPlacing to raise £2.0 million
30th Jun 20257:00 amRNSLiver fibrosis breakthrough with Optimer® platform
25th Jun 20257:00 amRNSAgreement with global life sciences leader
30th May 20257:00 amRNSUnilever second Optimer development programme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.